COVID-19 pushes J&J to slash guidance; vaccine initiative on track

Johnson & Johnson cut its guidance Tuesday as it braced for its bottom line to take a hit from the pandemic. The update came as the company topped consensus estimates for the first quarter and reiterated the timeline for its COVID-19 vaccine program.

Johnson & Johnson (NYSE:JNJ) added about $16.5

Read the full 492 word article

How to gain access

Continue reading with a
two-week free trial.